Filing Context and Reporting Period
The provided filing is an Annual Report on Form 10-K for Enochian BioSciences Inc. (Nasdaq: ENOB), not Lunai Bioworks Inc. It covers the fiscal year ended June 30, 2022, with comparative fiscal 2021 results. The filing was signed and filed on February 27, 2023. The requested period, “2021 Q4,” does not match the filing’s annual reporting period.
Enochian is a preclinical biotechnology company developing allogeneic cell and gene therapies for solid tumors, HIV, and hepatitis B. It has no approved products and has generated no product revenue.
Key Financial Metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Operating expenses | $116.1 million | $23.4 million | Up 396% |
| Research and development | $8.4 million | $15.7 million | Down 47% |
| General and administrative | $14.3 million | $7.6 million | Up 90% |
| Operating loss | $116.1 million | $23.4 million | Higher loss |
| Net loss | $113.4 million | $26.7 million | Up 324% |
| Basic and diluted loss per share | $2.16 loss | $0.57 loss | Higher loss per share |
| Net cash used in operating activities | $15.7 million | $20.6 million | Improved by $4.9 million |
| Cash and cash equivalents | $9.2 million | $20.7 million | Down $11.5 million |
| Working capital | $3.1 million | $19.0 million | Down $15.9 million |
| Total liabilities | $12.0 million | $14.9 million | Down $2.9 million |
| Accumulated deficit | $204.3 million | $90.9 million | Higher deficit |
Material Changes Versus Prior Period
- FY2022 net loss increased by $86.7 million, principally because of a $93.3 million non-cash impairment charge related to indefinite-lived in-process research and development licenses.
- General and administrative expense increased by $6.8 million, including higher stock-based compensation, salaries, recruiting costs, and legal fees.
- Research and development expense declined by $7.3 million, primarily because FY2021 included $10.8 million of coronavirus and influenza license-related costs. The decrease was partly offset by higher contract research and manufacturing costs.
- Cash used in operations improved to $15.7 million from $20.6 million, but financing proceeds fell sharply to $4.3 million from $32.6 million.
- Cash declined to $9.2 million, and working capital fell substantially. Management stated that existing cash was insufficient to fund the next twelve months of operations.
- The Company recorded $5.5 million of stock-based compensation in FY2022 compared with $1.4 million in FY2021.
- The Company abandoned its pan-coronavirus and influenza programs and prioritized oncology, particularly the pancreatic cancer program, and an HIV therapeutic vaccine program.
Liquidity, Debt, and Going Concern
- The auditor included an explanatory paragraph stating that recurring losses, cash usage, and dependence on additional financing raise substantial doubt about the Company’s ability to continue as a going concern.
- At June 30, 2022, cash was $9.2 million, total liabilities were $12.0 million, and debt included $1.2 million of convertible notes and approximately $4.6 million of notes payable, net of discount.
- Management planned to seek additional equity or debt financing. The filing cautions that financing may be unavailable or may cause significant dilution.
- After year-end, the $1.2 million convertible notes were amended to mature February 28, 2024, with interest increased to 12%. The $5 million promissory note was extended to November 30, 2023 and secured, along with the amended convertible notes, by a lien on substantially all Company assets.
- The Company received $4.7 million from Lincoln Park equity-line sales during FY2022. Access to that facility was no longer available as of October 17, 2022.
Outlook, Management Commentary, and Risks
- Management expected no revenue for the foreseeable future unless product candidates receive regulatory approval and achieve market acceptance.
- ENOB-DC-11, the lead pancreatic cancer program, was in moderately advanced preclinical development. Management targeted confirmatory in vivo data by early 2023, a potential Pre-IND submission in early or mid-2023, and possible human trials by late 2023 or the first half of 2024.
- ENOB-HV-12, an HIV therapeutic vaccine, was in advanced preclinical development with non-human primate studies underway. Management discussed potential Pre-IND activity in mid-2023 and Phase I trials by mid-to-late 2024.
- ENOB-HV-01 was deprioritized and sublicensed to Caring Cross because of cost and development duration. ENOB-HV-21 was also deprioritized, with no near- or medium-term IND planned. The HBV program remained early preclinical and was secondary to oncology.
- COVID-19 had not materially affected operations as of the filing, but it caused experimental delays, supply-chain constraints, staffing limitations, and higher animal-study costs.
- Material risks include failure of preclinical or clinical studies, regulatory delays, novel-therapy safety concerns, reliance on third-party researchers and manufacturers, intellectual-property disputes, inability to raise capital, dilution, and competition from better-funded companies.
- The Company disclosed securities class actions, derivative litigation, regulatory inquiries, and other disputes related to its relationship with former co-founder Serhat Gümrükçü and the Company’s commercial prospects. The Company also alleged that certain defendants manipulated or fabricated study results and sought recovery of approximately $25 million.
- A demand letter asserted more than $64 million in damages relating to alleged breaches of an investor-rights agreement. The Company denied the allegations.
- As of June 30, 2022, disclosure controls and internal control over financial reporting were determined to be ineffective because the Company lacked adequate resources to address complex accounting matters.
- The Company received Nasdaq notices for untimely periodic filings and had not regained compliance as of the filing date, creating a potential delisting risk.
Most Important Facts to Verify
- Issuer and period: Confirm that the intended filing is Enochian BioSciences Inc.’s FY2022 Form 10-K, rather than a filing for Lunai Bioworks Inc. or a 2021 quarterly period.
- Going concern: Review the auditor’s going-concern language and management’s financing plans, including cash runway and the availability of new funding.
- Non-cash impairment: Assess the assumptions supporting the $93.3 million IPR&D impairment and the remaining $61.6 million IPR&D carrying value.
- Litigation and investigations: Review the status, potential exposure, insurance coverage, and accounting treatment of the securities, derivative, and related-party disputes.
- Debt security: Verify the amended maturities, 12% interest terms, and liens covering substantially all Company assets.
- Regulatory milestones: Verify whether the projected Pre-IND and clinical-development timelines were achieved after the filing date.
- Nasdaq compliance: Confirm whether the Company subsequently filed delinquent reports and regained compliance or faced delisting action.
- Internal controls: Review remediation plans for ineffective disclosure controls and internal control over financial reporting.